Local timeDecember 9, 2023-On the 12th, the 65th American Society of Hematology (ASH) Annual Meeting was held in San Diego, USA. As one of the largest and most comprehensive international academic conferences in the field of hematology worldwide, experts from the global hematology research community gathered here to discuss the latest basic frontiers, new treatment methods and protocols, and disease management strategies for blood disorders.
Notably, at this conference, Cellular Biomedicine Group (Shanghai) Ltd presented two immunooncology projects.Data Release for Clinical Studies on the Drug Development of C-CAR039 and C-CAR066Both products demonstrated excellent response rates, durability of response, and favorable safety profiles.In terms of alleviating persistence, after30With a median follow-up period of about several months, achieving such a remission rate is indeed impressive, demonstrating best-in-class potential and expected to bring excellent therapeutic outcomes for patients.
Among them,C-CAR039 for the treatment of relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) is a novel second-generation 4-1BB dual-target CAR-T with an optimized bispecific antigen-binding domain that can simultaneously target CD19 and CD20. It is capable of continuously eliminating CD19/CD20 single-positive or double-positive tumor cells in vivo. Research on C-CAR039 shows,In evaluableIn r/r NHL patients, the median follow-up time was 30.0 months, the overall response rate was 91.5%, and the complete response rate was 85.1%.
AndC-CAR066 is a novel second-generation CAR-T product targeting the CD20 antigen, used for treating relapsed/refractory large B-cell lymphoma (LBCL) that has failed prior CD19 CAR-T therapy. Research on C-CAR066 shows,In the pastIn LBCL patients who failed CD19 CAR-T treatment, the median follow-up time was 27.7 months, the overall response rate was 92.9%, and the complete response rate was 57.1%.。
It is understood that this yearIn May, Cellular Biomedicine Group (Shanghai) Ltd entered into an exclusive global cooperation agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for C-CAR039 and C-CAR066. According to the terms of the agreement, Janssen has obtained the exclusive development rights for C-CAR039 and C-CAR066 outside of China, as well as the priority option for development within China. Both research projects have been approved by the U.S. Food and Drug Administration (FDA) for Phase 1b clinical trials. Notably, C-CAR039 has been granted Fast Track (FT) and Regenerative Medicine Advanced Therapy (RMAT) designations by the FDA for the treatment of relapsed/refractory and diffuse large B-cell lymphoma (r/rDLBCL), as well as Orphan Drug Designation (ODD) for the treatment of follicular lymphoma (FL).
